Meeting
2015 ASCO Annual Meeting
Ponatinib efficacy and safety in patients (pts) with advanced gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor (TKI) failure: Results from a phase 2 study.
Authors
Michael C. Heinrich
Knight Cancer Institute and Portland VA Medical Center, Oregon Health & Science University, Portland, OR
Michael C. Heinrich , Margaret von Mehren , George D. Demetri , Jonathan A. Fletcher , Jichao G Sun , David Kerstein , Maureen G Conlan , Suzanne George
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT01874665
Citation
J Clin Oncol 33, 2015 (suppl; abstr 10535)
DOI
10.1200/jco.2015.33.15_suppl.10535
Abstract #
10535
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.
First Author: Hidekazu Hirano
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Peak study: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib in combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
First Author: Michael C. Heinrich
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase 1/1b first-in-human study of IDRX-42, a novel oral tyrosine kinase inhibitor (TKI), in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs).
First Author: Suzanne George
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: A multicenter, retrospective study.
First Author: Weili Yang